REFERENCES :

1. Rxlist, The Internet Drug Index. http://www.rxlist.com/script/main/art.asp?articlekey= 3285 (accessed Sep 05, 2011)
2. World Health Organization. http://www.who.int/mediacentre/factsheets/fs999/en/index. html (accessed Sep 05, 2011)
3. Wikipedia The Free Encyclopedia. http://en.wikipedia.org/wiki/Anticonvulsant (accessed Sep 05, 2011)
4. Wikipedia The Free Encyclopedia. http://en.wikipedia.org/wiki/Automatism (medicine) (accessed Sep 05, 2011)
5. Baichwal Anand R., Deborah A. Neville. (2001), Adding value to the products' Life-Cycle Management: Product Enhancement Through Drug Delivery Systems. Drug Development & Delivery. [Online] Vol. 1, No. 1, http://www.drugdeliverytech.com/ME2/dirmod.asp?sid=&nm=&type=Publishing&mod=Publications%3A%3AArticle&mid=8F3A7027421841978F18BE895F87F791&tier=4&id=7F75A1275F7B461698F9EBC9554CFC7C (accessed Sep 05, 2011)
6. Intelli Drug, Controlled Drug Delivery. http://www.intellidrug.asm-poland.com.pl/ Business_opportunity, k=20.html (accessed Sep 21, 2011)
7. Wiki Invest. http://www.wikinvest.com/wiki/Antiepileptic_Drug_Market (accessed Sep 05, 2011)
8. University of Meryland, Medical Center. http://www.umm.edu/patiented/articles/what_specific_medications_used_epilepsy_000044_7.htm (accessed Sep 05, 2011)
9. Topamax. http://www.topamax.com/tools-resources--prescribing-information.html (accessed Sep 05, 2011)
10. Chunbo Zhang; Patrick Kwan; Zhong Zuo; Larry Baum. (2011), The transport of antiepileptic drugs by P-glycoprotein. Adv. Drug Deliv. Rev. (Article in Press)., ADR-12222; No of Pages 13.
11. Willmore James L. (1998) Antiepileptic drug therapy in the elderly. Pharmacol. Ther., Vol. 78, No. 1, 9-16.
12. Nabih M. Ramadan; Thomas M. Buchanan. (2006), New and future migraine therapy. Pharmacology & Therapeutics. 112, 199–212.
13. Owen T. Jones. (2002), Ca^{2+} channels and epilepsy. European Journal of Pharmacology. 447, 211 – 225.

14. Johannessen Landmark C. (2011), Host factors affecting antiepileptic drug delivery – Pharmacokinetic variability. Adv. Drug Deliv. Rev. (Article in Press). ADR-12200, No. of pages 15.
15. Marco Pappagallo. (2003), Newer Antiepileptic Drugs: Possible Uses in the Treatment of Neuropathic Pain and Migraine. Clinical Therapeutics. Vol. 25, No. 10, 2506-2538.
16. Mike Namaka; Colin R.; Gramlich; Dana Ruhlen; Maria Melanson; Ian Sutton; Joanne Major. (2004), A treatment algorithm for neuropathic pain. Clinical Therapeutics. Vol. 26, No. 7, 951-979.
17. Walker M. C.; Patsalos P. N. (1995), Clinical pharmacokinetics of new antiepileptic drugs. Phurmac. Ther. Vol. 67. No. 3, pp. 351-384.
18. Stephen D. Silberstein. (2006), Preventive treatment of migraine. TRENDS in Pharmacological Sciences. Vol.27, No.8, pp. 410-415.
19. Michelle K. Bazil; Carl W. Bazil. (1997), Recent Advances in the Pharmacotherapy of Epilepsy. Clinical Therapeutics. Vol. 19, No. 3, 369-382.
20. Elizabeth J. Donner; O. Carter Snead. (2006), New Generation Anticonvulsants for the Treatment of Epilepsy in Children. NeuroRx: The Journal of the American Society for Experimental Neuro Therapeutics. Vol. 3, 170–180.
21. Stephen D. Silberstein; Elinor Ben-Menachem; Richard P. Shank; Frank Wiegand. (2005), Topiramate Monotherapy in Epilepsy and Migraine Prevention. Clinical Therapeutics. Vol 27, No. 2, 154-165.
22. Emilio Perucca. (1997), A pharmacological and clinical review on topiramate, a new antiepileptic drug. Pharmacological Research. Vol. 35, No. 4, 241-256.
23. Michael A. Rogawski; Carl W. Bazil. (2008), New Molecular Targets for Antiepileptic Drugs: α2δ, SV2A, and Kv7/KCNQ/M Potassium Channels. Curr Neurol Neurosci Rep. 8(4): 345–352.
24. Ali R Rajabi Siahboomi. (2003), An Over view of Current Oral Modified Release Technologies. Business Briefing : Pharmatech, pp.181-184.
25. Shajahan Abdul; Anil V. Chandewar; Sunil B. Jaiswal. (2010), A flexible technology for modified-release drugs: Multiple-unit pellet system (MUPS). Journal of Controlled Release. Vol. 147, 2-16.
26. Emilio Perucca. (2009), Extended-Release Formulations of Antiepileptic Drugs: Rationale and Comparative Value. Epilepsy Currents. Vol. 9, No. 6, pp. 153–157.

27. Praveen Khullar; Amol Kulkarni; Nilesh Jaiswal. (2010), Pharmaceutical Pellets: Industrial applications & Innovative perspective. Pharma Times. Vol 42, No. 04, pp. 30-32.
28. Kumar Vikash; Mishra Santosh Kumar; Lather Amit; Vikas; Singh Ranjit. (2011), Multiple unit dosage form- Pellet and Pelletization Techniques: An Overview. IJRAP. 2 (1), 121-125.
29. Niklas Sandler; Jukka Rantanen; Jyrki Heinamaki; Meike Romer; Martti Marvola; Jouko Yliruusi. (2005), Pellet Manufacturing by Extrusion-Spheronization Using Process Analytical Technology. AAPS PharmSciTech. 6 (2) Article 26.
30. Md. Akhlaquer Rahman; Alka Ahuja; S. Baboota; Bhavna; Vikas Bali; Nitin Saigal; Javed Ali. (2009), Recent Advances in Pelletization Technique for Oral Drug Delivery: A Review. Current Drug Delivery. 6, 122-129.
31. Saurabh Srivastava; Garima Mishra; (2010), Fluid Bed Technology: Overview and Parameters for Process Selection. Intern. J. of Pharmaceutical Sciences and Drug Research. 2(4): 236-246.
32. Shirzad Azarmi; Wilson Roa; Raimar Lobenberg. (2007), Current perspectives in dissolution testing of conventional and novel dosage forms. International Journal of Pharmaceutics. 328, 12–21.
33. Siepmann J.; Lecomte F.; Bodmeier R.; Lecomte F.; Bodmeier R. (1999), Diffusion-controlled drug delivery systems: calculation of the required composition to achieve desired release profiles. Journal of Controlled Release. 60, 379–389.
34. Goran Frenning; Asa Tunon; Goran Alderborn. (2003), Modelling of drug release from coated granular pellets. Journal of Controlled Release. 92, 113–123.
35. Atul M. Mehta. (1986), Scale up considerations in the fluid bed processor for controlled release products, Pharmaceutical Technology.
36. Rambali B.; Baert L.; Massart D. L. (2003), Scaling up of the fluidized bed granulation process. International Journal of Pharmaceutics. 252, 197–206.
37. Yassin Farag; Claudia S. Leopold. (2011), Development of shellac-coated sustained release pellet formulations. European Journal of Pharmaceutical Sciences. 42, 400–405.
38. Rajesh. N; Siddaramaiah; Gowda D.V. (2011), Formulation and evaluation of controlled release behaviour of diltiazem hydrochloride from the pellets of chitosan and microcrystalline cellulose blends. Pharma Science Monitor. Vol-2, Issue-2, 152-170.
39. Xingna Zhao; Guofei Li; Lili Zhang; Xiaoguang Tao; Tingting Guan; Mo Hong; Xing Tang. (2010), Preparation and evaluation of nicotinic acid sustained-release pellets combined with immediate release simvastatin. International Journal of Pharmaceutics. 400, 42–48.

40. Lian-Dong Hu; Yang Liu; Xing Tang; Qian Zhang. (2006), Preparation and in vitro/in vivo evaluation of sustained-release metformin hydrochloride pellets. European Journal of Pharmaceutics and Biopharmaceutics. 64, 185–192.
41. Yam Noymi V; Shivanand Padmaja; Kimbel Rhea; Allphin Clark P; Wong Patrick S. (2005), Stepwise delivery of topiramate over prolonged period of time. U.S. Patent publication no. 2005,136,108, June 23, 2005.
42. Jenkins Scott A.; Liversidge Gary. (2006), Topiramate pharmaceutical composition. U.S. Patent publication no. 2006,121,112, June 08, 2006.
43. Nghiem Tien; Jackson Graham. (2008), Controlled release formulations using intelligent polymers. U.S. Patent publication no. 2008,292,700, Nov 27, 2008.
44. Park Jin Woo; Shin Young Hee; Shin Kwang Hyun; Kim Jung Ju. (2007), Sustained-Release Preparations Containing Topiramate and the Producing Method Thereof. U.S. Patent publication no. 2007,224,281, Sep 27, 2007.
45. Liang, Likan.; Wang, Hua.; Bhatt, Padmanabh P.; Vieira, Michael L. (2008), Sustained-release formulation of Topiramate. U.S. Patent publication no. 2008,118,557, May 22, 2008.
46. Mandal Jayanta Kumar; Pandya Nitesh Nalinchandra; Pillai Sumitra Ashok; Maheshwari Kirti Bansidhar. (2009), Controlled release formulation comprising anti-epileptic drugs. U.S. Patent publication no. 2009,196,923, Aug 06, 2009.
47. Almarsson Orn; Remenar Julius; Peterson Matthew L. (2003), Topiramate salts and compositions comprising them. U.S. Patent 6,699,840, Sep 04, 2003.
48. Chen Andrew Xian; Kigin Patricia D. (2008), Sustained release compositions using wax-like materials. U.S. Patent publication no. 2008,220,079, Sep 11, 2008.
49. Vaya Navin; Karan Rajesh S.; Nadkarni Sunil S.; Gupta Vinod K. (2006), Novel drug delivery system. U.S. Patent US7976871, Jan 26, 2006.
50. Barker Nicholas; Wolfe Janet L. (2006), Pharmaceutical formulations for sustained release. U.S. Patent publication no. 2006,198,815, Sep 07, 2006.
51. Nangia Avinash; Verma Daya D.; Jacob Jules. (2008), Topiramate compositions and methods of enhancing its bioavailability. U.S. Patent publication no. 2008,085,306, Apr 10, 2008.
52. Najarian Thomas; Tam Peter Y.; Wilson Leland F. (2009), Novel topiramate compositions and an escalating dosing strategy for treating obesity and related disorders. U.S. Patent publication no. 2009,304,789, Dec 10, 2009.

53. Cardinal John R; James Jack Lawrence; Melsopp Elsie; Oakley David M. (2010), Extended-Release Pharmaceutical Formulations. U.S. Patent publication no. 2010,159,001, Jun 24, 2010.
54. Remon Jean Paul; Debunne Ann. (2002), Controlled release pharmaceutical pellet compositions for reducing side effects of drugs. International Patent publication no. WO 02,17877, Mar 07, 2002.